Shots:

• Dyno to receive an $18M up front & is eligible to receive additional payments during research, $235M in clinical & sales milestone along with royalties for resulting products with a total deal value of ~$1.6M
• The collaboration will combine Dyno’s AI-powered AAV vector engineering capabilities with Astellas gene therapies expertise in AAV-based pipeline assets to develop AAV vectors for gene therapy using Dyno’s CapsidMap platform
• Dyno will design novel AAV capsids with improved functional properties for gene therapy while Astellas will conduct preclinical, clinical &commercialization activities including manufacturing of gene therapy products using the novel capsids

  Ref: Astellas | Image: Astellas